Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. - Wikidata - wikimedia - TriplyDB

Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.

Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.

http://www.wikidata.org/entity/Q36014004

about

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma Pulmonary adenocarcinoma: a renewed entity in 2011 Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck Field cancerization in non-small cell lung cancer: implications in disease pathogenesis.Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma.The BATTLE to personalize lung cancer prevention through reverse migration.(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.Evolving concepts in lung carcinogenesis Preneoplasia of lung cancer EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy.Enriching the molecular definition of the airway "field of cancerization:" establishing new paradigms for the patient at risk for lung cancer Personalizing lung cancer prevention through a reverse migration strategy.Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors.EGFR mutations and the terminal respiratory unit.Progressive endobronchial premalignancy: marked by original CIN.Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.An intermittent approach for cancer chemoprevention.Detecting EGFR alterations in clinical specimens-pitfalls and necessities.Consistent mutation status within histologically heterogeneous lung cancer lesions.

P2860

Q26785713-D9851DFB-5622-448F-8026-53C946D4651A Q26828860-690ED2E3-510E-47FB-92C7-C25A8FCB8182 Q27853224-C1208999-45F9-49EF-8C95-CB9C8EE4A5B1 Q28303718-4748F925-F787-4659-8F18-F6D9FA362FEA Q28395348-CE0D1756-ADDA-4AEB-9FC4-E90287B772B9 Q33411775-E755B061-FC9B-4ACE-B06D-56E2E4EDA692 Q33531781-2650761E-2441-438F-BC40-7CCAAD302395 Q33599090-93D5C37A-3821-4159-A976-BC1AEBA1497F Q33769820-55527A6B-58C1-41C5-9947-BDD802AC1B2E Q34103766-BB2F27A0-3D95-4428-A7F5-01F51C851C5D Q34159011-3011F969-928F-4388-8297-7FAA3B517D32 Q34159125-AD374F7A-878F-4015-98E2-C64D3107C809 Q34272221-F2C97999-CE56-45B5-9A15-CEAC65840C42 Q34308740-F56974DA-1638-41F6-9CE9-2261EE6ED209 Q34568606-7FC0D757-406E-4C62-904C-1D73C03D1B97 Q34809743-FD6B72BB-F1E6-4C55-A895-7A36D690A296 Q35164306-D5C57D21-8EEA-4CD0-A692-6A543EB2756D Q35176964-10F6DDA1-7922-4FBF-8416-1E0547B66068 Q35208501-4A077C55-CDA1-4EEA-8CA4-6A23FE994131 Q35609644-EC0811D5-90A5-46D8-8309-CF1C170A1580 Q36178320-50BFEF27-42DF-4A03-B2E2-2A3E0D133AA6 Q36190383-7799FA87-01EF-49FD-9A85-4F737713DF4B Q36250691-9EC66AAA-8456-40A4-AAC4-5A36551DA140 Q36358309-70559EB3-72F1-4F9E-87A3-9541A88C6DDE Q37029665-984F2A98-C8EA-4EBA-9A01-430586DDEC46 Q37080513-71E48141-3B08-4704-AC45-C674AF34A2C8 Q37175654-9289C0C2-40E6-4EAB-9846-B1886AC50325 Q37334996-9AB7ACC4-FFFA-4AA3-8F55-82FD091F96CC Q37438296-D280D784-9AE9-4C9C-A12B-E05BF725DF9B Q37628928-78A90FC3-9A89-4B76-B4B6-A22BA7D46F98 Q37687922-98CACD25-8509-473D-9581-B2B06DF2897E Q42958680-A0CE4E2B-069A-4139-843E-4FAE04634166 Q48096086-EDFA3322-80AD-4AFC-BCD9-E1DE3BA5C650 Q51662524-14B7CDEC-606C-4182-9648-1369EED0A74D Q53085284-AF540DC7-7424-484C-A72C-80A69AABBE04 Q54520483-791CF079-0CD1-45B4-BA76-C16EA528393F

P2860

Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.

http://www.wikidata.org/entity/Q36014004

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Epidermal growth factor recept ...... ssion of lung adenocarcinomas.

@ast

Epidermal growth factor recept ...... ssion of lung adenocarcinomas.

@en

type

label

Epidermal growth factor recept ...... ssion of lung adenocarcinomas.

@ast

Epidermal growth factor recept ...... ssion of lung adenocarcinomas.

@en

prefLabel

Epidermal growth factor recept ...... ssion of lung adenocarcinomas.

@ast

Epidermal growth factor recept ...... ssion of lung adenocarcinomas.

@en

P1433

Q36014004-312AE27B-720E-407C-814E-3620721978EC

P1476

Q36014004-5D7AB24C-03A7-4245-AA50-4EBDDABBE1D6

P2093

Q36014004-7B3C1776-B127-4C48-AB9C-A1D4056DFD7F

Q36014004-986EAF84-A4C7-427E-845C-C06EE1C7DFBD

Q36014004-9C32FDEC-179E-4757-8FF4-C6074E121D0B

Q36014004-DE0377DA-B7CA-4C12-A809-92BC03270913

Q36014004-F6429CB9-DC01-4596-B176-D0EC9E445898

P2860

Q36014004-04A0E28C-8704-47B3-A1F1-7B4ADA32389E

Q36014004-0A8565EE-9CF7-4DDD-95A0-89D5EB0E1FA8

Q36014004-2076A977-9B7C-40FD-AA78-3CE890D530F3

Q36014004-29FA882E-909A-48A7-89EF-5F93F56E68AE

Q36014004-2EBA6C5E-140D-4BDB-BFD2-BA45CF8A8B15

Q36014004-31CC48BE-BE4D-4431-9622-5852FDB3426B

Q36014004-3EFC9B23-6947-485E-95AD-063E9B2E83F5

Q36014004-3FB9380A-2006-4A28-BEA9-DFE168AD4184

Q36014004-41C3EC08-99CD-4E1F-8ED3-6036CF44A814

Q36014004-46839613-EA51-4275-B1EF-000EC2CB5DE2

P304

Q36014004-B85965B7-3AFA-4118-8D13-D8DB17067EC6

P31

Q36014004-A0D22A5F-E519-4B41-B65D-299678D34F0E

P356

Q36014004-D99F77AC-636A-4885-A4FB-F63146709243

P433

Q36014004-A849717A-B64A-476B-9861-DD2E566DB359

P478

Q36014004-A6B222A9-7594-4CAB-A886-FEBF95CE8690

P50

Q36014004-5396CAC7-07CF-4136-8A72-29EC0C2F45FC

Q36014004-B8F01A4A-B328-4C97-8D19-A5B136AE624F

P577

Q36014004-9FEC719B-A1E3-486A-ADFA-8D90F541AFCE

P5875

Q36014004-311C31A1-1BBA-478D-8CEE-4658CFBDA00D

P698

Q36014004-458E0D9F-1768-423B-8F5E-FD4060E42A92

P921

Q36014004-30335D1E-A38F-4697-AF75-A6370BDACDC6

Q36014004-C94EDD96-1AF3-43E4-B2CC-2411E735AC9F

P932

Q36014004-500B4772-554C-4E76-8C68-4A6B8305C09F

P356

1940-6207.CAPR-08-0032

P1433

Cancer Prevention Research

P1476

Epidermal growth factor recept ...... ssion of lung adenocarcinomas.

@en

P2093

Ana C Xavier

http://www.w3.org/2001/XMLSchema#string

Cesar Moran

http://www.w3.org/2001/XMLSchema#string

Marileila Varella-Garcia

http://www.w3.org/2001/XMLSchema#string

Natalie Ozburn

http://www.w3.org/2001/XMLSchema#string

Ximing Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Early glandular neoplasia of the lung

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Revisions in the International System for Staging Lung Cancer

Clonal analysis of human colorectal tumors

Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.

The clonal origin and clonal evolution of epithelial tumours.

P304

192-200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1940-6207.CAPR-08-0032

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Ignacio I Wistuba

Erminia Massarelli

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23782193

http://www.w3.org/2001/XMLSchema#string

P698

19138956

http://www.w3.org/2001/XMLSchema#string

P921

P932

3369271

http://www.w3.org/2001/XMLSchema#string